Clinical Research in Cardiology

, Volume 95, Issue 5, pp 254–260 | Cite as

Effect of transcoronary ablation of septal hypertrophy on clinical outcome in hypertrophic obstructive cardiomyopathy associated with atrial fibrillation

  • Ludger Obergassel
  • Thorsten Lawrenz
  • Frank H. Gietzen
  • Frank Lieder
  • Christian Leuner
  • Horst Kuhn
  • Christoph Stellbrink



Relatively few reports on the clinical impact of atrial fibrillation (AF) in hypertrophic obstructive cardiomyopathy (HOCM) are available. The aims of our study are to report the effect of transcoronary ablation of septal hypertrophy (TASH) on clinical outcome in HOCM associated with AF and to evaluate the influence of AF on symptoms and quality of life in HOCM.

Patient and methods

In 80 consecutive patients (38 f, mean age 56 ± 17 years) with severely symptomatic HOCM referred for interventional treatment, we analyzed the prevalence of AF based on 240 Holter ECG recordings and patients’ history, retrospectively. Symptoms, quality of life, number of hospital admissions and hemodynamic performance were obtained in all patients before and after TASH. Mortality was additionally investigated by letter and telephone contact.


The overall prevalence of AF was 29%. Paroxysmal AF was detected in 17 pts (21.3%), persistent AF in 5 pts (6.3%). Only 1 pt (1.3%) suffered from permanent AF. Symptoms due to AF were present in 52.6% of the AF patients. Quality of life score was markedly improved after TASH (15.9 ± 3.8 vs. 20.7 ± 3.8, p < 0.001) with no difference between sinus rhythm and atrial fibrillation. However, hospital admissions were more frequent in the AF group (0.85 ± 1.84 vs. 0.28 ± 0.81, p = 0.03) in 32 ± 13 months. AF patients suffered more often from syncope before TASH (30 ± 70% vs. 10 ± 30%, p = 0.008). Two patients with sinus rhythm at baseline died after 32 ± 13 months from cardiovascular cause.


Atrial fibrillation is the major cardiac arrhythmia in severe HOCM. The majority of AF patients demonstrate AF specific symptoms. The paroxysmal type of atrial fibrillation dominates by far. Both patients with and without atrial fibrillation showed similar quality of life with marked improvement after TASH.

Key words

Hypertrophic obstructive cardiomyopathy atrial fibrillation transcoronary alcohol ablation of septal hypertrophy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Crijns HJGM, Tjeerdsma G, de Kam PJ, Boomsma F, van Gelder C, van den Berg MP (2000) Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J 21:1238–1245CrossRefPubMedGoogle Scholar
  2. 2.
    Doll N, Fabricius AM, Gummert JF, Krakor R, Hindricks G, Kottkamp H, Mohr FW (2003) Surgical treatment of therapy resistant atrial fibrillation. Z Kardiol 92:712–720CrossRefPubMedGoogle Scholar
  3. 3.
    Ehrlich JR, Hohnloser SH (2005) Pharmacological cardioversion of atrial fibrillation. Z Kardiol 94:14–22CrossRefPubMedGoogle Scholar
  4. 4.
    Faber L, Seggewiss H, Gleichmann U (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation 98(22):2415–2421PubMedGoogle Scholar
  5. 5.
    Faber L, Seggewiss H, Welge D, Fassbender D, Ziemssen P, Schmidt HK, Gleichmann U, Horstkotte D (2003) Predicting the risk of atrioventricular conduction lesions after percutaneous septal ablation for obstructive hypertrophic cardiomyopathy. Z Kardiol 92:39–47CrossRefPubMedGoogle Scholar
  6. 6.
    Faber L, Seggewiss H, Gietzen FH, Kuhn H, Boeckstegers P, Neuhaus L, Seipel L, Horstkotte (2005) Catheterbased septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: Follow–up results of the TASHregistry of the German Cardiac Society. Z Kardiol 94:516–523CrossRefPubMedGoogle Scholar
  7. 7.
    Fananapazir L, Tracy CM, Leon MB, Winkler JB, Cannon RO 3rd, Bonow RO, Maron BJ, Epstein SE (1989) Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation 80:1259–1268PubMedGoogle Scholar
  8. 8.
    Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, Treese N, Breithardt G (2004) Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 25:1385–1394CrossRefPubMedGoogle Scholar
  9. 9.
    Gallagher MM, Camm J (1998) Classification of atrial fibrillation. Am J Cardiol 82:18N–28NCrossRefPubMedGoogle Scholar
  10. 10.
    Gietzen FH, Leuner ChJ, Raute–Kreinsen U, Dellmann A, Hegselmann J, Strunk–Mueller C, Kuhn HJ (1999) Acute and long–term results after transcoronary ablation of septal hypertrophy (TASH): Catheter interventional treatment for hypertrophic cardiomyopathy. Eur Heart J 20:1342–1354CrossRefPubMedGoogle Scholar
  11. 11.
    Gietzen FH, Leuner CJ, Obergassel L, Strunk–Mueller C, Kuhn H (2002) Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, New York Heart Assocociation functional class III and IVand outflow obstruction only under provocable conditions. Circulation 106(4):454–459CrossRefPubMedGoogle Scholar
  12. 12.
    Kirchhof P, Engelen M, Franz MR, Ribbing M, Wasmer K, Breithardt G, Haverkamp L, Eckardt (2005) Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation. Basic Res Cardiol 100:112–121CrossRefPubMedGoogle Scholar
  13. 13.
    Kuhn H, Gietzen FH, Leuner Ch, Schäfers M, Schober O, Strunk–Müller C, Obergassel L, Freick M, Gockel B, Lieder F, Reite–Kreinsen U (2000) Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol 89(Suppl 4:IV):41–54Google Scholar
  14. 14.
    Kuhn H, Seggewiss H, Gietzen FH, Boekstegers P, Neuhaus L, Seipel L (2004) Catheter–based therapy for hypertrophic obstructive cardiomyopathy: First in–hospital outcome analysis of the German TASH Registry. Z Kardiol 93:23–31CrossRefPubMedGoogle Scholar
  15. 15.
    Kuhn H, Gietzen F, Leuner C, Gerenkamp T (1997) Induction of subaortic septal ischemia to reduce obstruction in hypertrophic obstructive cardiomyopathy: studies to develop a new catheter based concept of treatment. Eur Heart J 18:846–851PubMedGoogle Scholar
  16. 16.
    Kuhn H, Lawrenz T, Lieder F, Gietzen F, Obergassel L, Strunk–Mueller C, Stolle B, Leuner CJ (2004) Alcohol septal ablation in the treatment of hypertrophic obstructive cardiomyopathy: a seven–year experience. In: Maron BJ (ed) Diagnosis and Management of Hypertrophic Cardiomyopathy, 1st edn. Blackwell Futura, Malden, pp 279–296Google Scholar
  17. 17.
    Lawrenz Th, Obergassel L, Lieder F, Leuner Ch, Strunk–Mueller C, Meyer zu Vilsendorf D, Beer G, Kuhn H (2005) Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy. PACE 28:1–6Google Scholar
  18. 18.
    Loogen F, Kuhn H, Gietzen F, Losse B, Schulte HD, Bircks W (1983) Clinical course and prognosis of patients with typical and atypical hypertrophic obstructive and with hypertrophic non–obstructive cardiomyopathy. Eur Heart J 4(Suppl F):145–153PubMedGoogle Scholar
  19. 19.
    López Gil M, Arribas F, Cosio FG (2000) Ventricular fibrillation incuced by rapid atrial rates in patients with hypertrophic cardiomyopathy. Europace 2:327–332CrossRefGoogle Scholar
  20. 20.
    Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, TenCate FJ, Wigle ED (2003) American college of cardiology/ european society of cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 24:1965–1991CrossRefPubMedGoogle Scholar
  21. 21.
    Obergassel L, Gietzen FH, Strunk– Mueller C, Meyer zu Vilsendorf D, Lawrenz T, Bartelsmeier, Kuhn HJ (2001) Does Transcoronary Ablation of Septal Hypertrophy (TASH) in Hypertrophic Cardiomyopathy (HOCM) Induce an Arrhythmogenic Substrate? Clinical Results and Holter–ECG–Data. PACE 24(4):694Google Scholar
  22. 22.
    Obergassel L, Lawrenz Th, Meyer zu Vilsendorf D, Gietzen FH, Strunk– Mueller C, Kuhn H (2001) His–Bündel– Ablation (HBA) bei hypertrophisch– obstruktiver Kardiomyopathie (HOCM) und tachykardem Vorhofflimmern. Z Kardiol 90(Suppl 5):V/76Google Scholar
  23. 23.
    Obergassel L, Lawrenz T, Gietzen FH, Strunk–Mueller C, Kuhn H (2002) Atrial fibrillation in hypertrophic obstructive cardiomyopathy: prevalence, symptoms and quality of live. Eur H Jour 23(Abstr Suppl):487Google Scholar
  24. 24.
    Olivotto I, Cecchi F, Casey SA, Dolora A, Traverse JH, Maron BJ (2001) Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 104:2517–2524PubMedGoogle Scholar
  25. 25.
    Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, McKenna WJ (1990) Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol 15:1279–1285PubMedCrossRefGoogle Scholar
  26. 26.
    Siegwart U (1995) Non surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346:211–214CrossRefGoogle Scholar
  27. 27.
    Sopher SM, Camm AJ (1996) Atrial fibrillation: maintenance of sinus rhythm versus rate control. Am J Cardiol 77:24ACrossRefPubMedGoogle Scholar
  28. 28.
    Stellbrink C (2005) Treatment of lifethreatening cardiac arrhythmias. Internist 46(3):275–284CrossRefPubMedGoogle Scholar
  29. 29.
    Ueng KC, Tsai TP, Tsai CF, Wu DJ, Lin CS, Lee SH, Chen SA (2001) Acute and long–term effects of atrioventricular junction ablation and VVIR pacemaker in symptomatic patients with chronic lone atrial fibrillation and normal ventricular response. J Cardiovasc Electrophysiol 12:303–309CrossRefPubMedGoogle Scholar
  30. 30.
    Wise DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalqist JE, Corley SD (AFFIRM Investigators) (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825–1833CrossRefGoogle Scholar

Copyright information

© Steinkopff-Verlag 2006

Authors and Affiliations

  • Ludger Obergassel
    • 1
    • 3
  • Thorsten Lawrenz
    • 1
  • Frank H. Gietzen
    • 2
  • Frank Lieder
    • 1
  • Christian Leuner
    • 1
  • Horst Kuhn
    • 1
  • Christoph Stellbrink
    • 1
  1. 1.Department of Cardiology and Internal Intensive MedicineThe Bielefeld Community Hospital, Academic Teaching Hospital of the University of MuensterBielefeldGermany
  2. 2.Department of CardiologyCentre of Cardiovascular MedicineBad Neustadt/SaaleGermany
  3. 3.Städtische Kliniken BielefeldKlinik für Kardiologie und Internistische IntensivmedizinBielfeldGermany

Personalised recommendations